Page 32 - Haematologica August 2018

M. de Charette et al.
Anticancer Agents. Cancer Cell. 2015;28(6):
690-714.
165.Ries CH, Cannarile MA, Hoves S, et al.
Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy. Cancer Cell. 2014;25(6):846-859.
166. Romano E, Kusio-Kobialka M, Foukas PG, et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci USA. 2015;112(19):6140-6145.
167. Arce Vargas F, Furness AJS, Litchfield K, et al. Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. Cancer Cell. 2018;33(4):649-663.e4.
168.Fuji S, Inoue Y, Utsunomiya A, et al. Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus- Host Disease, Nonrelapse Mortality, and Overall Mortality. J Clin Oncol. 2016;34(28):3426-3433.
169. Ninomiya S, Narala N, Huye L, et al. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood. 2015;125 (25):3905-3916.
170. Hanafi L-A, Gauchat D, Godin-Ethier J, et al. Fludarabine Downregulates Indoleamine 2,3-Dioxygenase in Tumors via a Proteasome-Mediated Degradation Mechanism. PLoS One. 2014;9(6):e99211.
171. Boice M, Salloum D, Mourcin F, et al. Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells. Cell. 2016;167(2):405-418.e13.
172. Launay E, Pangault C, Bertrand P, et al. High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis. Leukemia. 2012;26(3):559.
173.Cheung K-JJ, Johnson NA, Affleck JG, et al. Acquired TNFRSF14 Mutations in Follicular Lymphoma Are Associated with Worse Prognosis. Cancer Res. 2010;70(22):9166- 9174.
174.Wu J, Wood GS. Reduction of Fas/CD95 Promoter Methylation, Upregulation of Fas
Protein, and Enhancement of Sensitivity to Apoptosis in Cutaneous T-Cell Lymphoma. Arch Dermatol. 2011;147(4):443-449.
175. Dong R, Dong R, Zhang M, et al. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review). Int J Mol Med. 2018;41(2):599-614.
176. Jelinek T, Mihalyova J, Kascak M, Duras J, Hajek R. PD-1/PD-L1 inhibitors in haemato- logical malignancies: update 2017. Immunology. 2017;152(3):357-371.
177. Llorente L, Richaud-Patin Y, García-Padilla C, et al. Clinical and biologic effects of anti– interleukin-10 monoclonal antibody admin- istration in systemic lupus erythematosus. Arthritis Rheum. 2000;43(8):1790-1800.
178.Vicari AP, Chiodoni C, Vaure C, et al. Reversal of Tumor-induced Dendritic Cell Paralysis by CpG Immunostimulatory Oligonucleotide and Anti–Interleukin 10 Receptor Antibody. J Exp Med. 2002;196(4): 541-549.
179. Ni X, Langridge T, Duvic M. Depletion of reg- ulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab. Oncoimmunology. 2015;4(7): e1011524.
1268
haematologica | 2018; 103(8)